TRANSPERS News: Faculty Position Recruitment; Publications in J Community Genetics and Genetics in Medicine; Collaborator Publications on the UK's 100,000 Genomes Project and Breast Cancer Evaluation
Letter from Center Director
Dear Colleagues:
TRANSPERS wishes all our colleagues and readers an incredibly Happy New Year!
We are excited to welcome the new year, new colleagues, and new projects.
This issue highlights our search for a new faculty member, accomplishments of our faculty, and publications from our Team.
As always, I welcome your engagement.
Best,
Kathryn A. Phillips, PhD
Highlights
TRANSPERS Seeks Assistant/Associate Professor
Washington Post cites Phillips: Alzheimer’s drug is for those with mild cognitive impairment. But who has that disorder?
Jeroen Jansen and Kathryn Phillips Identified as Top Cited Scientists in their Fields for a second year in a row!

Publications
Understanding and Overcoming Barriers to Equitable Hereditary Cancer Testing for Latinx Patients
TRANSPERS Program Manager, Michael Douglas, MS, led a team that recently published their findings in Journal of Community Genetics to describe key challenges and possible solutions for HCP testing in the Latinx population. We found potential challenges related to the sustainability of low-cost testing and out-of-pocket expenses for patients, access to cascade testing for family members, and pathogenic variants specific to Latinx population. Providers questioned whether current laboratory payment programs that decrease barriers to testing are sustainable and suggested solutions for accessing cascade testing and ensuring variants specific to the Latinx population were included in testing.
TRANSPERS and NIH Clinical Sequencing Evidence-Generation Research (CSER) Study identifies key challenges on Payer Coverage of Genome vs. Exome Sequencing

The researchers conducted interviews with representatives of private payer organizations on considerations and evidentiary needs for coverage of Genome Sequencing (GS) and Exome Sequencing (ES). Payers see advantages to GS vs. ES and are open to broader GS coverage but need more proof of these advantages to consider them in coverage decision-making. Key next steps include establishing evidence of benefits in specific clinical scenarios, developing quality standards, and ensuring transparency of laboratory methods.
Forthcoming Publication on Coverage for Multi-Cancer Early Detection “Liquid Biopsy” Tests in Health Affairs
Presentations
- Patricia Deverka, MD, Deputy Director of TRANSPERS: “Multi-cancer Early Detection Screening Tests: Anticipating and Addressing Likely Considerations for Payer Coverage and Patient Access.” The Early Detection of Cancer Conference, October 6-8, 2021.
- Kathryn Phillips, PhD, Founder and Director of TRANSPERS: “Who Will Benefit vs. Who Will Pay? Reconciling the Irreconcilable Dilemmas of Genomic Medicine.” Stanford Center for Biomedical Ethics, December 14, 2021.
- Kathryn Phillips, PhD and Jeroen Jansen, PhD: “Applying Precision Medicine to ADRD: Addressing Challenges of Payment and Economic Value.” Johns Hopkins Economics of Alzheimer’s Disease & Services, December 15, 2021.
Upcoming
- Kathryn Phillips, PhD: “Who Will Benefit Vs. Who Will Pay? Reconciling the Irreconcilable Dilemmas of Genomic Medicine.” Columbia Center for Research on Ethical, Legal & Social Implications of Genetics, March 14, 2022.
Collaborator News
Long-Time TRANSPERS Collaborator Allison Kurian, Stanford, selected to serve as a Komen Scholar for 3 years
HOLIDAY CELEBRATION
Kathryn Phillips celebrates the holidays with TRANSPERS post-doc Cheng Chen and other Clinical Pharmacy Post-docs!
